<DOC>
	<DOCNO>NCT01490840</DOCNO>
	<brief_summary>This study evaluate effect individualize web-based physical training fingolimod -treated patient .</brief_summary>
	<brief_title>Effect Physical ACtivity Fingolimod Treated patiEnts ( PACE ) With Relapsing-remitting Multiple Sclerosis</brief_title>
	<detailed_description>In study , plan randomize 226 participant . However , 178 participant randomize timeframe 2 year 8 month . Therefore , study terminate due slow enrollment low participant compliance physical training schedule .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<criteria>Subjects relapse remit MS define 2010 revise McDonald criterion Patients Expanded Disability Status Scale ( EDSS ) score 03.5 ( include ) Immunomodulatory treatment prescribe fingolimod least one month prior baseline Fatigue score assess mFIS equal great 14 screen Neurologically stable evidence relapse within 30 day prior inclusion date Patients treat : systemic corticosteroid immunoglobulin within 1 month prior randomization ; immunosuppressive medication azathioprine , cyclophosphamide , methotrexate within 3 month prior randomization ; monoclonal antibody ( include natalizumab ) within 3 month prior randomization ; mitoxantrone within 6 month prior randomization cladribine time . Patients medically unstable condition , assess primary treat physician site . Patients follow cardiovascular condition : history cardiac arrest ; history myocardial infarction current unstable ischemic heart disease ; history angina pectoris due coronary spasm history Raynaud syndrome Heart failure ( NYHA IIIIV ) severe cardiac disease determine investigator ; history presence seconddegree AV block , Type II thirddegree AV block patient receive Class Ia ( ajmaline , disopyramide , procainamide , quinidine ) III antiarrhythmic drug ( e.g. , amiodarone , bretylium , sotalol , ibulitide , azimilide , dofelitide ) ; prove history sick sinus syndrome sinoatrial heart block ; uncontrolled hypertension Clinically relevant internal disease ( e.g . uncorrected anemia ) orthopedic disease ( e.g . scoliosis ) might interfere physical training Any severe disability clinical impairment prevent patient meet study requirement investigator ` discretion Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Fatigue</keyword>
	<keyword>MS</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Exercise</keyword>
	<keyword>Physical activity</keyword>
	<keyword>Physical training</keyword>
	<keyword>Fingolimod</keyword>
</DOC>